Fig 1: Unique protein signatures are observed for eculizumab-treated patients.(A) Volcano plot comparing azathioprine and eculizumab constructed by plotting log2 values of protein fold-changes between the 2 treatment groups against their –log10 P values. Differential regulation of expression levels was calculated by 1-way ANOVA. The horizontal dashed line indicates the significance cutoff value, which was set to P < 0.05. The vertical dashed lines indicate a fold-change cut-off of 1.0. (B) Volcano plot comparing treatment-naive and eculizumab-treated patients. (C–F) Protein abundance of significantly regulated serum proteins of interest in A displayed as raincloud plots. Whiskers are 1.5 IQR. To account for multiple comparisons, statistical significance was corrected by the false discovery rate (FDR) approach. A threshold of q = 5% was used for FDR. One-way ANOVA testing was used for comparison of multiple groups. N = 10 per group. ALOX5, arachidonat-5-lipoxygenase; APOC3/4, apolipoprotein CIII/IV; C4BP, C4b-binding protein; CRP, C-reactive protein; MPO, myeloperoxidase; PRDX2/6, peroxiredoxin-2/6; TF, transferrin. ***P < 0.001, **P < 0.01, *P < 0.05.